Company intelligence / Profile preview

Algalif

Reykjanesbær, Icelandalgalif.is ↗

Ownership: Private
Development stage: Commercial

Overview

Algalif commercially supplies high-grade natural astaxanthin and beta-glucan ingredients derived from microalgae for use in nutraceuticals, food, beverages, sports nutrition, and personal care. The company operates a cGMP-compliant facility powered by renewable geothermal energy in Iceland. No clinical trial results reported; products are marketed based on established safety/efficacy of astaxanthin as a supplement.

Therapeutic areas: ImmunologyOtherDermatologyCardiovascularOphthalmologyNeurology
Modalities: Natural product (astaxanthin)Beta-glucan (Nutramunity Beta Glucan)Microalgae-derived ingredients
Industry: Food & Nutrition

Drug pipeline

1 asset

astaxanthin

Commercial

Indications: Dietary supplement

Beyond the preview

Go deeper on Algalif.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Algalif.

Explore the full profile